Genprex (GNPX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the company’s lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq. Similarly, the European Patent Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex Stockholders Approve Key Proposals at Annual Meeting
- Genprex Announces Stockholder Letter and Corporate Update
- Genprex Announces Positive Preclinical Results for GPX-002
- Genprex presents positive preclinical research from studies of GPX-002
- Genprex Announces Positive Data for Diabetes Therapy